Poniard Pharmaceuticals Completes Enrollment Of Phase 2 Picoplatin Trial In Colorectal Cancer
May 15th 2008Drug InformationColorectal Cancer
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating picoplatin combination chemotherapy for the first-line treatment of metastatic colorectal cancer (CRC). Early data from this trial are expected in the second half of 2008.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
